Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Marker Therapeutics (MRKR) EBT (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed EBT for 11 consecutive years, with $8.6 million as the latest value for Q4 2025.

  • Quarterly EBT rose 69.32% to $8.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.0 million through Dec 2025, down 8.71% year-over-year, with the annual reading at -$12.2 million for FY2025, 14.02% down from the prior year.
  • EBT for Q4 2025 was $8.6 million at Marker Therapeutics, up from -$2.0 million in the prior quarter.
  • The five-year high for EBT was $8.9 million in Q4 2023, with the low at -$10.9 million in Q2 2021.
  • Average EBT over 5 years is -$3.5 million, with a median of -$4.1 million recorded in 2023.
  • The sharpest move saw EBT surged 403.73% in 2023, then plummeted 88.49% in 2025.
  • Over 5 years, EBT stood at -$9.8 million in 2021, then skyrocketed by 70.0% to -$2.9 million in 2022, then soared by 403.73% to $8.9 million in 2023, then plummeted by 42.82% to $5.1 million in 2024, then skyrocketed by 69.32% to $8.6 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at $8.6 million, -$2.0 million, and -$4.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.